The raised guidance and Atera commercial launch are the key catalysts. Monitor Atera adoption and consumables pull-through in Q4; the raised midpoint implies ~$630M for FY2026, above the prior $620M midpoint.
Price Chart
Executive Summary
10x Genomics reported Q3 2026 revenue of $150.7M (+1% YoY), slightly above the $147.8M consensus, and a GAAP net loss per share of $(0.15), which is narrower than the Street consensus estimate of $(0.29). The company raised its full-year 2026 revenue guidance to $625M-$635M (from $610M-$630M) and began commercial shipments of the Atera platform, a key catalyst.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $150.7M, +1% YoY vs $149.0M in Q3 2025
- GAAP net loss per share $(0.15) vs $(0.22) in Q3 2025; Street consensus was $(0.29)
- Gross margin improved to 75% from 67% a year ago
- Full-year 2026 revenue guidance raised to $625M-$635M from $610M-$630M
- Began global commercial shipments of Atera spatial biology platform
- Introduced Sentira cloud analysis platform with NVIDIA and Anthropic AI
- Cash and marketable securities $575.7M as of September 30, 2026
Financial Impact
Revenue $150.7M, net loss $(19.4M), operating loss $(16.1M), gross margin 75%
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Single Cell Consumables | $93.1M | +0.7% |
| Spatial Consumables | $41.2M | +16.4% |
| Single Cell Instruments | $3.8M | -23.2% |
| Spatial Instruments | $3.1M | -56.5% |
| Services | $9.0M | +11.0% |
Risk Factors
- Revenue growth remains modest at 1% YoY; reliance on Atera ramp for acceleration
- Operating loss persists at $(16.1M); path to profitability not yet established
- Litigation expenses could fluctuate; contingent consideration liabilities remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-071025 |
| Document: txg-20261105.htm | 0001628280-26-071025 |
| Document: 0001628280-26-071025-index-headers.html | 0001628280-26-071025 |
| Document: 0001628280-26-071025-index.html | 0001628280-26-071025 |
| Document: 0001628280-26-071025.txt | 0001628280-26-071025 |
| 8-K Data (Synthetic) | 0001628280-26-071025 |
Track record
28 reports on TXG
1 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +8.89% at T+60 after the Aug 19, 2026 report. 2 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $55.40 Now $54.99 −0.74% settles Feb 12
- Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
- Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing No price data
- Nov 5, 202611d ago Press Release Mixed 5/10 Entry $59.28 Now $54.99 −7.24% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $65.29 Now $54.99 −15.78% settles Feb 1
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $71.55 Now $54.99 −23.14% settles Jan 21
- Oct 7, 20265w ago SC 13G/A Neutral 2/10 Entry $77.28 Now $54.99 −28.84% settles Jan 5
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $85.71 Now $54.99 −35.84% settles Dec 21
- Sep 22, 20267w ago 144 Neutral 2/10 Entry $75.62 Now $54.99 −27.28% settles Dec 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers